NCT02008851View on ClinicalTrials.gov

A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Chronic Kidney Disease
Interventions
BIOLOGICAL

Neo-kidney augment

Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient

Trial Locations (5)

27514

UNC Medical Center, Chapel Hill

37235

Vanderbilt University, Nashville

60637

University of Chicago Medicine, Chicago

70112

LSU Health Care Services, New Orleans

02120

Brigham & Women's Hospital, Boston

Sponsors

Lead Sponsor

Tengion
All Listed Sponsors
lead

Tengion

INDUSTRY